Logo image of CHRA

CHARAH SOLUTIONS INC (CHRA) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:CHRA - US15957P3038 - Common Stock

2.17 USD
+0.08 (+3.83%)
Last: 4/3/2023, 8:20:29 PM
Fundamental Rating

1

CHRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 80 industry peers in the Commercial Services & Supplies industry. CHRA has a bad profitability rating. Also its financial health evaluation is rather negative. CHRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CHRA has reported negative net income.
In the past year CHRA has reported a negative cash flow from operations.
CHRA Yearly Net Income VS EBIT VS OCF VS FCFCHRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

The profitability ratios for CHRA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRA Yearly ROA, ROE, ROICCHRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 100 -100

1.3 Margins

The Gross Margin of CHRA (1.79%) is worse than 80.00% of its industry peers.
In the last couple of years the Gross Margin of CHRA has declined.
The Profit Margin and Operating Margin are not available for CHRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
CHRA Yearly Profit, Operating, Gross MarginsCHRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

CHRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRA has less shares outstanding
Compared to 1 year ago, CHRA has an improved debt to assets ratio.
CHRA Yearly Shares OutstandingCHRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
CHRA Yearly Total Debt VS Total AssetsCHRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

CHRA has an Altman-Z score of 0.08. This is a bad value and indicates that CHRA is not financially healthy and even has some risk of bankruptcy.
CHRA's Altman-Z score of 0.08 is on the low side compared to the rest of the industry. CHRA is outperformed by 80.00% of its industry peers.
A Debt/Equity ratio of 7.56 is on the high side and indicates that CHRA has dependencies on debt financing.
CHRA has a Debt to Equity ratio of 7.56. This is amonst the worse of the industry: CHRA underperforms 91.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC6.34%
CHRA Yearly LT Debt VS Equity VS FCFCHRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.14 indicates that CHRA should not have too much problems paying its short term obligations.
CHRA's Current ratio of 1.14 is on the low side compared to the rest of the industry. CHRA is outperformed by 61.25% of its industry peers.
A Quick Ratio of 1.09 indicates that CHRA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.09, CHRA perfoms like the industry average, outperforming 48.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.09
CHRA Yearly Current Assets VS Current LiabilitesCHRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

CHRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -260.00%.
CHRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 146.66%.
Measured over the past years, CHRA shows a small growth in Revenue. The Revenue has been growing by 2.04% on average per year.
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%

3.2 Future

The Earnings Per Share is expected to decrease by -347.79% on average over the next years. This is quite bad
Based on estimates for the next years, CHRA will show a small growth in Revenue. The Revenue will grow by 7.09% on average per year.
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CHRA Yearly Revenue VS EstimatesCHRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CHRA Yearly EPS VS EstimatesCHRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRA Price Earnings VS Forward Price EarningsCHRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRA Per share dataCHRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

CHRA's earnings are expected to decrease with -347.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%

More info and screens

2

5. Dividend

5.1 Amount

CHRA has a Yearly Dividend Yield of 1.26%.
In the last 3 months the price of CHRA has falen by -70.95%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
CHRA's Dividend Yield is a higher than the industry average which is at 0.89.
Compared to the average S&P500 Dividend Yield of 1.87, CHRA is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.26%

5.2 History

CHRA is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DP0%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
CHRA Yearly Income VS Free CF VS DividendCHRA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M -60M

More info and screens

CHARAH SOLUTIONS INC

NYSE:CHRA (4/3/2023, 8:20:29 PM)

2.17

+0.08 (+3.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)03-30 2023-03-30
Earnings (Next)05-08 2023-05-08
Inst Owners88.22%
Inst Owner Change-3.06%
Ins Owners66.98%
Ins Owner Change0%
Market Cap7.33M
Revenue(TTM)318.13M
Net Income(TTM)-40.90M
Analysts48.57
Price Target90.78 (4083.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.26%
Yearly Dividend0.3
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.03%
Min EPS beat(2)-58.73%
Max EPS beat(2)-23.34%
EPS beat(4)0
Avg EPS beat(4)-80.85%
Min EPS beat(4)-130.17%
Max EPS beat(4)-23.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.78%
Min Revenue beat(2)-4.89%
Max Revenue beat(2)-0.67%
Revenue beat(4)1
Avg Revenue beat(4)0.34%
Min Revenue beat(4)-4.89%
Max Revenue beat(4)8.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6257.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-899.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-900.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.7
EYN/A
EPS(NY)-11.31
Fwd EYN/A
FCF(TTM)-24.58
FCFYN/A
OCF(TTM)-23.06
OCFYN/A
SpS94.13
BVpS7.03
TBVpS-25.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.79%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%
F-Score1
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.09
Altman-Z 0.08
F-Score1
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)46.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-387.5%
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Sales Q2Q%-3.11%
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%
EBIT growth 1Y-259.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.36%
EBIT Next 3Y26.32%
EBIT Next 5Y22.98%
FCF growth 1Y-5990.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-931.71%
OCF growth 3YN/A
OCF growth 5YN/A

CHARAH SOLUTIONS INC / CHRA FAQ

Can you provide the ChartMill fundamental rating for CHARAH SOLUTIONS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CHRA.


What is the valuation status for CHRA stock?

ChartMill assigns a valuation rating of 3 / 10 to CHARAH SOLUTIONS INC (CHRA). This can be considered as Overvalued.


Can you provide the profitability details for CHARAH SOLUTIONS INC?

CHARAH SOLUTIONS INC (CHRA) has a profitability rating of 0 / 10.


What is the expected EPS growth for CHARAH SOLUTIONS INC (CHRA) stock?

The Earnings per Share (EPS) of CHARAH SOLUTIONS INC (CHRA) is expected to decline by -436.41% in the next year.


Is the dividend of CHARAH SOLUTIONS INC sustainable?

The dividend rating of CHARAH SOLUTIONS INC (CHRA) is 1 / 10 and the dividend payout ratio is 0%.